These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
178 related articles for article (PubMed ID: 21170760)
1. Enhanced oncolysis mediated by Coxsackievirus A21 in combination with doxorubicin hydrochloride. Skelding KA; Barry RD; Shafren DR Invest New Drugs; 2012 Apr; 30(2):568-81. PubMed ID: 21170760 [TBL] [Abstract][Full Text] [Related]
2. Systemic targeting of metastatic human breast tumor xenografts by Coxsackievirus A21. Skelding KA; Barry RD; Shafren DR Breast Cancer Res Treat; 2009 Jan; 113(1):21-30. PubMed ID: 18256929 [TBL] [Abstract][Full Text] [Related]
3. Potent oncolytic activity of human enteroviruses against human prostate cancer. Berry LJ; Au GG; Barry RD; Shafren DR Prostate; 2008 May; 68(6):577-87. PubMed ID: 18288643 [TBL] [Abstract][Full Text] [Related]
4. Oncolysis of vascular malignant human melanoma tumors by Coxsackievirus A21. Au GG; Lindberg AM; Barry RD; Shafren DR Int J Oncol; 2005 Jun; 26(6):1471-6. PubMed ID: 15870858 [TBL] [Abstract][Full Text] [Related]
5. Enterovirus capsid interactions with decay-accelerating factor mediate lytic cell infection. Newcombe NG; Johansson ES; Au G; Lindberg AM; Barry RD; Shafren DR J Virol; 2004 Feb; 78(3):1431-9. PubMed ID: 14722298 [TBL] [Abstract][Full Text] [Related]
6. Plasmacytoid dendritic cells orchestrate innate and adaptive anti-tumor immunity induced by oncolytic coxsackievirus A21. Müller LME; Holmes M; Michael JL; Scott GB; West EJ; Scott KJ; Parrish C; Hall K; Stäble S; Jennings VA; Cullen M; McConnell S; Langton C; Tidswell EL; Shafren D; Samson A; Harrington KJ; Pandha H; Ralph C; Kelly RJ; Cook G; Melcher AA; Errington-Mais F J Immunother Cancer; 2019 Jul; 7(1):164. PubMed ID: 31262361 [TBL] [Abstract][Full Text] [Related]
7. Systemic therapy of malignant human melanoma tumors by a common cold-producing enterovirus, coxsackievirus a21. Shafren DR; Au GG; Nguyen T; Newcombe NG; Haley ES; Beagley L; Johansson ES; Hersey P; Barry RD Clin Cancer Res; 2004 Jan; 10(1 Pt 1):53-60. PubMed ID: 14734451 [TBL] [Abstract][Full Text] [Related]
8. Oncolytic Coxsackievirus A21 as a novel therapy for multiple myeloma. Au GG; Lincz LF; Enno A; Shafren DR Br J Haematol; 2007 Apr; 137(2):133-41. PubMed ID: 17391493 [TBL] [Abstract][Full Text] [Related]
9. Enhanced cellular receptor usage by a bioselected variant of coxsackievirus a21. Johansson ES; Xing L; Cheng RH; Shafren DR J Virol; 2004 Nov; 78(22):12603-12. PubMed ID: 15507647 [TBL] [Abstract][Full Text] [Related]
10. Oncolytic Immunotherapy for Bladder Cancer Using Coxsackie A21 Virus: Using a Bladder Tumor Precision-Cut Slice Model System to Assess Viral Efficacy. Relph K; Annels N; Smith C; Kostalas M; Pandha H Methods Mol Biol; 2020; 2058():249-259. PubMed ID: 31486043 [TBL] [Abstract][Full Text] [Related]
11. The Effects of Mesenchymal Stem Cells Loaded with Oncolytic Karbalaee R; Mehdizadeh S; Ghaleh HEG; Izadi M; Kondori BJ; Dorostkar R; Hosseini SM Curr Cancer Drug Targets; 2024; 24(9):967-974. PubMed ID: 38310465 [TBL] [Abstract][Full Text] [Related]
12. Novel role for decay-accelerating factor in coxsackievirus A21-mediated cell infectivity. Newcombe NG; Beagley LG; Christiansen D; Loveland BE; Johansson ES; Beagley KW; Barry RD; Shafren DR J Virol; 2004 Nov; 78(22):12677-82. PubMed ID: 15507656 [TBL] [Abstract][Full Text] [Related]
13. Doxorubicin synergizes with 34.5ENVE to enhance antitumor efficacy against metastatic ovarian cancer. Bolyard C; Yoo JY; Wang PY; Saini U; Rath KS; Cripe TP; Zhang J; Selvendiran K; Kaur B Clin Cancer Res; 2014 Dec; 20(24):6479-94. PubMed ID: 25294909 [TBL] [Abstract][Full Text] [Related]
14. Doxorubicin hydrochloride enhanced antitumour effect of CEA-regulated oncolytic virotherapy in live cancer cells and a mouse model. Xiao B; Ying C; Chen Y; Huang F; Wang B; Fang H; Guo W; Liu T; Zhou X; Huang B; Liu X; Wang Y J Cell Mol Med; 2020 Nov; 24(22):13431-13439. PubMed ID: 33251723 [TBL] [Abstract][Full Text] [Related]
15. Engineering Oncolytic Coxsackievirus A21 with Small Transgenes and Enabling Cell-Mediated Virus Delivery by Integrating Viral cDNA into the Genome. Sam M; Selman M; Zhao W; Jung J; Willingham A; Phan U; Starling GC; Gao Q J Virol; 2023 May; 97(5):e0030923. PubMed ID: 37070982 [TBL] [Abstract][Full Text] [Related]
16. Oncolytic Immunotherapy for Bladder Cancer Using Coxsackie A21 Virus. Annels NE; Arif M; Simpson GR; Denyer M; Moller-Levet C; Mansfield D; Butler R; Shafren D; Au G; Knowles M; Harrington K; Vile R; Melcher A; Pandha H Mol Ther Oncolytics; 2018 Jun; 9():1-12. PubMed ID: 29989024 [TBL] [Abstract][Full Text] [Related]
17. Analysis of ICAM-1 Expression on Bladder Carcinoma Cell Lines and Infectivity and Oncolysis by Coxsackie Virus A21. Relph K; Arif M; Pandha H; Annels N; Simpson GR Methods Mol Biol; 2023; 2684():319-327. PubMed ID: 37410244 [TBL] [Abstract][Full Text] [Related]
18. Oncolysis of malignant human melanoma tumors by Coxsackieviruses A13, A15 and A18. Au GG; Beagley LG; Haley ES; Barry RD; Shafren DR Virol J; 2011 Jan; 8():22. PubMed ID: 21241513 [TBL] [Abstract][Full Text] [Related]
19. Cordycepin enhances Epstein-Barr virus lytic infection and Epstein-Barr virus-positive tumor treatment efficacy by doxorubicin. Du Y; Yu J; Du L; Tang J; Feng WH Cancer Lett; 2016 Jul; 376(2):240-8. PubMed ID: 27063964 [TBL] [Abstract][Full Text] [Related]